Introduction
Valproate (VPA) is a major antiepileptic drug with a broad spectrum of antiepileptic activity used in both adults and children.
1,2 However, there is increasing concern about the possible effects of VPA on reproductive endocrine function. 3 These include testicular atrophy, reduced or absent spermatogenesis and atrophy of the prostate, epididymis and seminal vesicles. [4] [5] [6] [7] [8] seems to affect the male reproductive system in a dose-dependent manner. 9 In agreement with a number of prior studies, one recent piece of research demonstrated that a dose of 400 mg/kg/day VPA was associated with testicular atrophy and histologically verified spermatogenetic arrest in male rats, while 200 mg/kg/day was not. 9 These animal studies on the effect of VPA on the reproductive and neuroendocrine system have largely focused on adult rats, although VPA is widely used for children as well as adults with epilepsy. 10 Oxcarbazepine (OXC) is a newer antiepileptic agent that has recently become increasingly used for childhood epilepsies.
11
There are few studies on the reproductive and endocrine effects of OXC in the literature. 3 One study demonstrated that after the replacement of carbamazepine (CBZ) with OXC, CBZ-induced alterations in the reproductive endocrine hormones in men Seizure 20 (2011) 203-207 returned to normal. 12 Another study determined that high doses of OXC monotherapy were associated with reproductive endocrine hormone abnormalities. 13 Sperm abnormalities have also been reported among men on OXC. 8 To the best of our knowledge, there have been no previous animal studies on the effects of OXC on testis morphology. Animal studies have three main advantages over human studies. They allow the investigation of the independent effects of the epilepsy itself and the effects of AEDs in isolation and permit the examination of gonadal morphology.
14 Our aim was to define the morphological effects of VPA and OXC, two antiepileptics widely used during childhood, on the rat testis. The results will provide important clues as to the reproductive effect of chronic use of these antiepileptics from childhood to adulthood in boys with epilepsy.
Materials and methods

Animals
Forty-two prepubertal male Wistar rats (age 21-24 days and weighing between 49.5 and 58.7 (g)) from the Gazi University Medical Faculty animal laboratory were used in this experimental study. All animals were housed in groups in plastic cages at constant room temperature (21-22 8C) in a 12 h-light/dark cycle (lights on at 07:00 a.m.). There were no specific restrictions regarding diet contents or quantities. Rats in all groups were given free access to food and water. Standard rat chow as routinely provided in the Gazi University Animal Experiments Laboratory was used. Feeding was performed under control conditions by veterinarians in the laboratory. The control and drug-administered groups consumed the same chow.
All animal experiments were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and were approved by the Gazi University Animal Care Committee.
Experimental procedure and dosing
Rats were divided into three experimental groups of 14 animals each. Group 1 (control group) was administered tap water via gavage, group 2 (VPA group) was administered 300 mg/kg/day VPA (Depakin 1 200 mg/1000 ml solution, Sanofi Dogu, Istanbul, Turkey), and group 3 (OXC group) was administered 100 mg/kg/ day OXC (Trileptal 1 60 mg/1000 ml solution, Novartis, Istanbul, Turkey). Ordinary drinking water was used as the control solution. Dosages of drugs in treatment groups 2 and 3 were determined according to rat weights. Under this regimen, a rat weighing 100 g in group 2 received 30 mg VPA based on a dose of 300 mg/kg/day, and a rat weighing 100 g in group 3 received 10 mg OXC based on a dose of 100 mg/kg/day. VPA solution at a concentration of 200 mg/ 1000 ml and 170 ml of OXC solution at a concentration of 60 mg/ 1000 ml were administered.
The VPA dose was adopted from a previous study by Røste et al. 15 An antiepileptic dose of OXC of 30 mg/kg has been proposed in the literature for single use, and higher for chronic use. 16 We used the higher dose of 100 mg/kg/day. All drugs were administered orally for 90 days at 12-h intervals in two separate doses via gavage prepared by bending the tip of the metal tube and coating it with silicone. During the study period, two rats in group 1, four rats in group 2, and three rats in group 3 were eliminated or lost for various reasons (mainly due to disease and death). Rats were weighed and sacrificed 12-16 h after the final drug administration by taking 6-8 ml intracardiac blood under anesthesia. The right and left testes were removed, weighed and fixed in 10% formalin for histological examination. The absolute testicular and epididymidis values were the weight of the organ on a sensitive scale. Relative weight was the ratio of absolute testicular weight to body weight. Four mm-thick tissue sections were stained with hematoxylin-eosin. Morphological descriptions of rat spermatogenetic cells and stages were used as a guide, while the quantitative analysis of spermatogenetic cells was performed as described in previous studies. [17] [18] [19] [20] [21] [22] Each slide was analyzed for three selected stages of the spermatogenic cycle (stages II, V and XII). For each stage, three separate seminiferous tubules were randomly selected and total cell count in these was assessed for spermatogonia, pachytene spermatocytes, zygotene spermatocytes, round spermatids and Sertoli cells. Relevant cells specific to each stage were included 17 and the ratio of spermatogenetic cells to Sertoli cells calculated. Indirect immunohistochemical staining (using p53 and TGF-b1 primary antibodies) and evaluation of apoptosis (TUNEL) were performed on 5 mm-thick paraffin tissue sections after 24-28 h.
One hundred serial sections from each testis were taken and every 10th, 20th, 30th, 40th, 50th, 60th, 70th, 80th, 90th and 100th slide chosen. These procedures were repeated for every single dye.
Biochemical assays
Blood samples were centrifuged for 10 min at 2500 rpm. Serum was removed and stored at À80 8C until measurement. Serum concentrations of monohydroxycarbamazepine (OXC active metabolite) were assessed using high performance liquid chromatography (HPLC). VPA levels were measured using the fluorescence polarization method in a Roche Cobas Integra 400 Analyzer and expressed as mg/ml.
Determination of apoptosis
The terminal deoxynucleotidyl-transferase-mediated dUTPbiotin nick end labeling (TUNEL) staining method was employed to determine apoptotic cell numbers. Testis sections were stained using an in situ cell death detection kit (ApopTag Plus Peroxidase In Situ S7101, Lot: 0603025277). Slices 5 mm in thickness were prepared from the paraffin blocks with an automated microtome device. Slides were incubated overnight at 60 8C. Sections were deparaffinized in xylene for 1 h and rehydrated with reduced alcohol series (100%, 95%, 85%, 70% and 60%). They were then incubated with 20 mg/ml proteinase K for 10 min. Washing with phosphate-buffered saline (PBS) at pH 7.4 was performed at each stage. Endogenous peroxidase activity was blocked with 3% H 2 O 2 . After washing with PBS, sections were incubated with equilibration buffer for 10-15 min and TdT enzyme (77 ml reaction buffer + 33 ml TdT enzyme mix, 1 ml TdT enzyme) for 60 min at 37 8C. Working strength stop/wash buffer (1:10) was applied for 10 min at room temperature and slices were incubated with antidigoxigenin conjugate for 30 min. After washing with PBS three times for 5 min, the sections were stained with DAB components to reveal TUNEL-positive cells and were counterstained with Methyl green. Histopathological signs and TUNEL-positive cells were evaluated by two independent observers blind to the study groups.
Immunohistochemical evaluation
Tissue samples from each group were fixed in neutral formalin for 72 h and processed for paraffin embedding. Sections 4-5 mm thick were processed for polylysine microscope slides. For immunohistochemical examination, the slides were stored in a microwave oven in a 0.01 M citrate buffer (Lot: 90030610D, Cat: AP-9003-500, LabVision, Fremont, CA, USA). Endogenous peroxidase activity was blocked in 3% hydrogen peroxide (Lot: AHP40114, Cat: TA-125-HP, LabVision, Fremont, CA, USA). Epitopes were stabilized using serum blocking solution (Lot: 41080981, Cat: 85-9043, Zymed, South San Francisco, USA) and five groups were then prepared from each slide. The first group was incubated with p53 (FL-93) (Rabbit Polyclonal IgG, Lot: A1806, Cat: SC-6243, Santa Cruz Biotechnology, CA, USA) and the second with transforming growth factor beta 1 (TGF-b1) (v) (Rabbit Polyclonal IgG, Lot: A1306, Cat: SC-146, Santa Cruz Biotechnology, California, USA) then diluted in UltraAb Diluent (Lot: 50481612, Cat: 00-3118, Zymed, South San Francisco, USA) for 60 min at room temperature. After incubation, the secondary antibody (Broad spectrum Histostain Plus, Lot: 41080981, Cot: 85-9043, Zymed, South San Francisco, USA) was applied. We then used 3-amino-9-ethylcarbazole (AEC) (Lot: 50481594, Cat: 00-2007, Zymed, South San Francisco, USA) for TGF-b1 antibodies and 3,3-diaminobenzidine tetrahydrochloride (DAB) (Lot: 40980870, Cat: 00-2020 Zymed, South San Francisco, USA) as chromogen for p53 antibodies. Slides were next counterstained with Mayer's hematoxylin and examined under an Olympus BH2 photo-light microscope. Serial sections were examined and immunolabeling patterns compared. Two observers blind to the samples evaluated the immunolabeling scores. Labeling intensity was graded semi-quantitatively and HSCOREs calculated using the equation HSCORE = P Pi (i + 1), where i = intensity of labeling with a value of 1, 2 or 3 (weak, moderate, or strong, respectively) and Pi is the percentage of labeled spermatogenic cells for each intensity, varying from 0% to 100%. 23 
Statistical analysis
Data were analyzed using SPSS. All data are expressed as means AE standard deviation. Comparisons between groups were tested using ANOVA or Kruskal-Wallis variance analysis followed by Tukey's multiple comparison test or the Mann-Whitney U test. Statistical significance was set at p < 0.05.
Results
Serum levels of antiepileptics were 23.74 AE 6.19 mg/ml for the VPA group and 2.08 AE 0.65 mg/ml for the OXC group.
Body and epididymidis weights were higher in the VPA group compared to the control and OXC groups, but these changes were not statistically significant (p > 0.05). Testis weights and relative testis weights in the VPA group were significantly lower compared to the control group (p = 0.007 and p = 0.001, respectively). There was no significant change in testis weights in the OXC group (p > 0.05). Body weights and the absolute and relative testicular and epididymidis weights of the controls and VPA and OXC groups undergoing 90 days of treatment are presented in Table 1 .
There was no necrosis, obvious depletion, disorganization or exfoliation of germ cells, tubular atrophy, inflammatory reaction or apparent pathological alteration in the Leydig cells in any of the slides examined. Sertoli cells were analyzed and counted in all the tubules evaluated. No vacuolation, swelling or cytoplasmics apoptotic bodies or phagocytized spermatogenic cells were observed in the Sertoli cells.
The ratio of spermatogonia, pachytene spermatocytes and round spermatocytes to Sertoli cells in stages II, V and XII, decreased in both the VPA and OXC groups, though this was not statistically significant (p > 0.05) ( Table 2) .
Apoptotic cell counts in the VPA group were higher than those in the control group (p < 0.0001) ( Fig. 1 and Table 3 ). The OXC group exhibited no significant difference in apoptotic count Table 1 The body weight, testis weight and relative testis weight of rats treated with control solution, VPA and OXC, during 90 days.
Control (n = 12)
VPA (n = 10) OXC (n = 11) compared to the control group. p53 immunoreaction in the OXC group was similar to the control group and significantly increased in the VPA group compared to the controls (p < 0.0001) ( Table 3) . TGF-b1 expression was observed in a significantly lower number of cells in the VPA group than in the control group (p < 0.05). Mild to moderate immunoreactivity was observed in the OXC group ( Fig. 2 and Table 3 ).
Discussion
In this study, we determined the morphological effects of VPA and OXC, two antiepileptics widely used during childhood, on the rat testis. While we established no significant effect of OXC on testis development up to adulthood, VPA use had significant effects.
The toxicological effects of VPA on testis of rats appear to be dose-and duration-related.
9,7 Nishimura et al. 7 reported spermatogenetic abnormalities after 4, 7 and 10 days of 500 mg/kg of VPA, the 10-day group exhibiting decreased testis weight. No abnormality was seen in similar groups at a 250 mg/kg dosage. Testicular atrophy was observed in Wistar rats following 90-day treatment at 400 mg/kg, but not after 200 mg/kg. 9 Much higher doses resulted in testicular atrophy in rats in earlier studies. 5 The 300 mg/kg dose in our study lay between the two doses used by Røste et al. 9 and resulted in decreasing testicular weight but no abnormal spermatogenesis. Rats' ages at the beginning of this research were 21-24 days, much younger than those in Røste et al.'s study. 9 We therefore speculate that a 300 mg kg/dose may be toxic at younger ages but not at older ones. Since only a single dose was used in this study, no information was obtained regarding the dose-dependent reproductive effects of VPA. In our study, in contrast to VPA, OXC gave rise to no significant change in either testis or epididymis weight. To the best of our knowledge, this is the first animal study to focus on the reproductive effects of OXC in male subjects. Mikkonen et al. 24 showed that OXC is not associated with changes in mean testicular volumes in boys and young men with epilepsy. Isojä rvi et al. 8 similarly indicated that OXC did not cause a significant testis volume change, but they reported that it did lead to sperm abnormalities. We did not examined sperm abnormalities in this study, but, in parallel with the literature, OXC caused neither testicular atrophy nor spermatogenetic arrest.
Except for minimal VPA-associated decreases in cell diameters, there was no necrosis, obvious depletion, disorganization or exfoliation of germ cells, tubular atrophy, inflammatory reaction or apparent pathological alteration in the Leydig cells in any of the slides examined from rats administered either VAP or OXC. Spermatogenetic cells and stages were evaluated, and quantitative analysis was performed based on previous reports and guidelines. [17] [18] [19] [20] [21] [22] The absence of any prominent morphological abnormality in our study does not correlate with the reduced testicular weights in the VPA group. This contrasts with Røste et al.'s study, 9 which showed atrophic tubules and spermatogenetic arrest at the prophase of the first meiosis correlated with a decrease in testis weights. Although the decrease in testis weight was not statistically significant, it is likely that declining numbers of spermatogonia, pachytene spermatocytes and round spermatocytes and minimal changes in cell diameters played a role in this decrease. In addition, increased apoptosis and p53 and decreased TGF-b1 staining may indicate definite levels of cell arrest and support decreases in the testis tissue. To the best of our knowledge, the literature contains no studies on the histopathological change in the testis tissue caused by OXC. This study demonstrates that in contrast to the negative effects in female rat ovarian tissues caused by OXC, 25, 26 it does not lead to prominent changes in spermatogenetic cells and stages in male rats. Apoptosis normally occurs in the first pubertal spermatogenetic wave in order to maintain a physiological quantity of germ cells, 27, 28 VPA has been shown to have proapoptotic effects on human and rat granulosa cells by increasing caspase-3 and positive staining using the TUNEL method. 25, 29 Bielecka and Obuchowicz 30 also noted the studies demonstrating its apoptosis-promoting effect and suggested that the ultimate effect depends on the drug dose and experimental model. We observed, for the first time in the literature, high apoptotic indices in the VPA group using the TUNEL method in testis tissue, which should properly be interpreted in view of the above-mentioned dual effects of VPA on apoptotic pathways and requires further experimentation. Three more recent studies have reported that OXC causes edema and apoptosis in retinal ganglion cells, and ovarian and endometrial tissues. 25, 26, 31 OXC gives rise to swelling and edema in some cells, leading to impairment and subsequent apoptosis and cell death in cell organelles. This particularly occurs in more aged cells. 25, 26 In contrast, we observed neither edema nor prominent apoptosis in the Sertoli cells, spermatocytes or spermatid cells of the rats administered OXC. We cannot account for this with the data available. Araú jo et al. 32 showed that, as demonstrated, OXC causes edema of the hippocampal neurons due to a decrease in mitochondrial membrane potential. The absence of edema and apoptosis in Sertoli cells, spermatocytes and spermatid cells may stem from OXC treatment causing no significant change in these cells' mitochondrial membrane potentials, in contrast to other cells. Table 3 The apoptotic cell counts, p53 and TGF-b1 expression in control, VPA and OXC groups.
Control (n = 12) VPA (n = 10) OXC (n = 11) [ ( ) T D $ F I G ] We calculated immunohistochemical HSCOREs for p53 and TGF-b1 stainings. It had previously been shown that enhanced p53 protein levels lead to cell cycle arrest, and high levels can trigger apoptosis in response to stress or DNA damage. 33, 34 As a potent inducer of apoptosis and regulator of cell growth, p53 is found in high concentrations in the testis. 35 The fact that in our study, intensity of labeling, HSCORE, and the percentages of follicles with moderate to strong labeling intensity for P53 increased in the VPA group along with high apoptotic cell counts supports this view. We also performed immunostaining for TGF-b1. This is known to pay a regulatory role in the hormonal control of adrenals in both sexes. TGF-b1 is expressed in spermatogonia, spermatocytes, and round but not elongated spermatids of both 21-day-old and adult Wistar rats. 36 Teerds and Dorrington 36 suggested that TGF-bs either promote the differentiation of germ cells in an autocrine fashion or else maintain the necessary communication with adjacent Sertoli cells. TGF-b1 has been shown to specifically stimulate and increase the DNA synthesis level of preleptotene spermatocytes in the spermatogenic stage VIIa. 37 Fertility in TGF-b1 null mutant mice has been demonstrated to be severely impaired. 38 Since we observed a low TGF-b1 expression in our study, it is possible that fertility may have been affected by treatment with VPA. However, these results for TGF-b1 cannot easily be applied to humans, as TGF-b1 has not been detected in human seminiferous tubular cells. 39 We did not investigate the hormonal effects of VPA. We cannot therefore say that these VPA-associated changed in the testis tissue are related to effects directly established by VPA at tissue level, and some of these effects may be ascribed to VPA-associated hormonal changes.
In conclusion, our study shows negative trophic effects of VPA on the testis but none caused by OXC. Quantitative morphological analysis of the spermatogenesis revealed no significant difference from the control group in either the VPA or OXC groups. Apoptotic index was elevated in the VPA group, with reduced TGF-b1 expression. These findings are partially in agreement with previous studies on the reproductive toxicity of VPA. We observed no serious abnormalities in the OXC group, and this is to our knowledge the first report on the effects of OXC on the rat testis.
Our findings should now be tested using different methods and larger numbers of subjects in future studies.
